LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION May 15, 2023 TO: Honorable Dan Patrick, Lieutenant Governor, Senate FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB773 by Parker (Relating to access to certain investigational drugs, biological products, and devices used in clinical trials by patients with severe chronic diseases.), As Passed 2nd House No significant fiscal implication to the State is anticipated. It is assumed that any costs associated with the bill could be absorbed using existing resources. Local Government ImpactNo significant fiscal implication to units of local government is anticipated. Source Agencies: b > td > 503 Texas Medical Board, 529 Health and Human Services Commission, 537 State Health Services, Department of LBB Staff: b > td > JMc, SD, NPe, ER, APA
LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION
May 15, 2023
TO: Honorable Dan Patrick, Lieutenant Governor, Senate FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB773 by Parker (Relating to access to certain investigational drugs, biological products, and devices used in clinical trials by patients with severe chronic diseases.), As Passed 2nd House
TO: Honorable Dan Patrick, Lieutenant Governor, Senate
FROM: Jerry McGinty, Director, Legislative Budget Board
IN RE: SB773 by Parker (Relating to access to certain investigational drugs, biological products, and devices used in clinical trials by patients with severe chronic diseases.), As Passed 2nd House
Honorable Dan Patrick, Lieutenant Governor, Senate
Honorable Dan Patrick, Lieutenant Governor, Senate
Jerry McGinty, Director, Legislative Budget Board
Jerry McGinty, Director, Legislative Budget Board
SB773 by Parker (Relating to access to certain investigational drugs, biological products, and devices used in clinical trials by patients with severe chronic diseases.), As Passed 2nd House
SB773 by Parker (Relating to access to certain investigational drugs, biological products, and devices used in clinical trials by patients with severe chronic diseases.), As Passed 2nd House
No significant fiscal implication to the State is anticipated.
No significant fiscal implication to the State is anticipated.
It is assumed that any costs associated with the bill could be absorbed using existing resources.
Local Government Impact
No significant fiscal implication to units of local government is anticipated.
Source Agencies: b > td > 503 Texas Medical Board, 529 Health and Human Services Commission, 537 State Health Services, Department of
503 Texas Medical Board, 529 Health and Human Services Commission, 537 State Health Services, Department of
LBB Staff: b > td > JMc, SD, NPe, ER, APA
JMc, SD, NPe, ER, APA